A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report. - Wikidata - awgldk - TriplyDB

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

http://www.wikidata.org/entity/Q35061729

about

Acute lymphoblastic leukaemia Monoclonal antibodies in acute lymphoblastic leukemia Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis.Phase I trial of a novel human monoclonal antibody mAb216 in patients with relapsed or refractory B-cell acute lymphoblastic leukemia Improving access to novel agents for childhood leukemia.Targeting paediatric acute lymphoblastic leukaemia: novel therapies currently in development Immunotherapy targets in pediatric cancer.In search of targeted therapies for childhood cancer.Molecular profiling of childhood cancer: Biomarkers and novel therapies Monoclonal antibody-based therapies: a new dawn in the treatment of acute lymphoblastic leukemia Advanced targeted, cell and gene-therapy approaches for pediatric hematological malignancies: results and future perspectives XmAb-5574 antibody demonstrates superior antibody-dependent cellular cytotoxicity as compared with CD52- and CD20-targeted antibodies in adult acute lymphoblastic leukemia cells.Pediatric Dosing and Body Size in Biotherapeutics.Antibody therapy for pediatric leukemia.Immunophenotyping of acute leukemia and lymphoproliferative disorders: a consensus proposal of the European LeukemiaNet Work Package 10.Antibody therapy for acute lymphoblastic leukemia.The future role of monoclonal antibody therapy in childhood acute leukaemias.Novel therapeutic strategies in adult acute lymphoblastic leukemia--a focus on emerging monoclonal antibodies.Acute lymphoblastic leukemia in adults: encouraging developments on the way to higher cure rates.Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.Novel targeted therapies in acute lymphoblastic leukemia.Clinical nanomedicine: a solution to the chemotherapy conundrum in pediatric leukemia therapy.Current therapy and novel agents for relapsed or refractory acute lymphoblastic leukemia.Antibody-based therapies in B-cell lineage acute lymphoblastic leukaemia.New targets for antibody therapy of pediatric B cell lymphomas.Optimizing drug therapy in pediatric SCT: focus on pharmacokinetics.Current status of antibody therapy in ALL.Pharmacokinetics and pharmacokinetic-pharmacodynamic relationships of monoclonal antibodies in children.Modern immunotherapy of adult B-lineage acute lymphoblastic leukemia with monoclonal antibodies and chimeric antigen receptor modified T cells.Novel approaches to pediatric leukemia treatment.Driving Toward Precision Medicine for Acute Leukemias: Are We There Yet?Lymphoblastic lymphoma: an updated review on biology, diagnosis, and treatment.Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia in Adults.Therapeutic antibody targeting of CD47 eliminates human acute lymphoblastic leukemia.Phase I trial of anti-GD2 monoclonal antibody hu3F8 plus GM-CSF: Impact of body weight, immunogenicity and anti-GD2 response on pharmacokinetics and survival.Haploidentical stem cell transplantation augmented by CD45RA negative lymphocytes provides rapid engraftment and excellent tolerability.

P2860

Q24602387-2850B0E7-4D8C-4173-AE6C-8A47CD9575F9 Q27022540-0CA16A1C-B99D-4DA8-96D2-56E88F3FF35C Q35224485-0247CD93-BC06-4F2C-A467-593D6689B81E Q35643010-B12A71E6-BB98-4055-B63F-2BC7EBFF1556 Q35688742-BA2283C5-29A3-425B-A388-541F9AD13889 Q35967452-44CBB0DB-B415-4A25-8A89-D770AAE00D92 Q35971029-5F6BEE4F-D9FC-4F25-9449-F31D46B28689 Q35971733-81D630E3-653F-42E5-A07B-A73CF4E03F4D Q36250783-8C4C8735-E9FD-4C11-A978-79C25F686717 Q36339717-B7F406DC-3356-425C-B63C-F9D3824A9700 Q36804215-09BE8ABE-3ED8-40DB-894D-E72F53B07253 Q36913118-011156E7-93E3-4080-A768-F267A530EDA6 Q37666711-8F24FCF8-894B-4B45-B957-3EA509AF0DA9 Q37725578-9BB91537-DE1B-4795-9F74-96FC81DAB48A Q37831107-C55BF4C7-A74C-4095-8910-E6002972B243 Q37994136-D0B40DF5-144E-4E64-922C-D4AA77E91A34 Q38033600-96099193-0965-4D97-B71E-563221B702CC Q38094099-D22AC7D6-5DFD-4D1C-A1FC-1754BB257A62 Q38095113-B9242407-FECD-4121-8CD5-0EBC2C2F5748 Q38097334-FDDC1BAF-A7E8-4E7A-8A4E-762AB5D3863D Q38120551-D026B32C-1B63-46AE-B137-BD66F385D92E Q38135276-7D54A1D8-0E4B-4CE7-B2C1-31BF99F12DF5 Q38164108-D8AEB972-8DE0-4600-8E8F-4CC1F75BA25A Q38224988-5C949791-9C86-412B-BCB6-2649DD666DCC Q38242984-C1ADB81A-1F4D-4857-8117-CCBF91A582DE Q38262916-FA001F12-F608-42F3-BE7B-5DD5F17EAF04 Q38266338-AFE80FBF-12EA-43B8-96FC-823931354848 Q38291356-02C279C8-3892-49E2-829A-3A1747F030C8 Q38312596-0D13F48D-3240-4393-9701-0C124ABFDAFA Q38500371-12DEC2DD-ED1A-48BD-8DE7-B6610F94CE12 Q38666159-93635B6D-4090-4821-8562-89B97722A1B7 Q38672607-DABEE196-DEF8-45C2-9E51-57A2408B1232 Q38840423-3301EA46-2A86-407A-99AD-8BFE9E295417 Q42616476-12B2F6F0-2B25-4673-AC3D-55D165BB4FCE Q47176287-A14B0191-1B88-4C66-9478-488441FFF553 Q53652856-EFED511D-B62F-4592-B7B1-AA7BDD2A799A

P2860

A phase II study of Campath-1H in children with relapsed or refractory acute lymphoblastic leukemia: a Children's Oncology Group report.

http://www.wikidata.org/entity/Q35061729

description

2009 nî lūn-bûn

@nan

2009 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@ast

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@en

type

label

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@ast

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@en

prefLabel

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@ast

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@en

P1433

Q35061729-A10F60C9-E6E0-4950-A7D8-9B21AE86F0DC

P1476

Q35061729-9B42130B-5D2E-4B72-8416-3787A320D874

P2093

Q35061729-62C7C528-C472-4309-BC8C-8357F9DC30BC

Q35061729-6D6FCC83-B616-41BB-8FDE-F7433AB03B3F

Q35061729-A741A08F-1C69-416B-8BD5-667E08DE0E6B

Q35061729-E0D1A049-40D5-44C6-BE8A-476D41C63B47

Q35061729-FA4FC3D4-6B8F-4C9A-829C-7E5E93971270

P2860

Q35061729-01ED175F-CC7A-4F29-9531-A5AD40BD45EC

Q35061729-061BF098-F9FB-4D67-B3AC-9BC730EA73AB

Q35061729-0DF779B5-A84B-4207-A355-79F980401074

Q35061729-0E50125B-1A01-4BC7-90B7-7DB9196717DC

Q35061729-1AB334E8-370E-4D1A-BF11-882DCB6773B0

Q35061729-2BA5EF31-B34A-4F6B-8FD5-9C383A8EBEDA

Q35061729-48770F9A-D2DE-412F-8784-0D100DB2C2CA

Q35061729-48EBA22A-AED9-40E9-B81D-4A3B223A87BA

Q35061729-4D1DD8E9-3543-4739-BFE1-858C323FFB79

Q35061729-8189B7A2-C8C4-47E5-B4A0-446EB4946D44

P304

Q35061729-205EE372-9C98-4C39-BDAF-2C52CFFEFFED

P31

Q35061729-DA9630DB-0414-4074-8C9F-75471B0A5185

P356

Q35061729-B48F4648-4D74-4CD5-B3C5-A02C5C65F24E

P433

Q35061729-E32C63A4-2281-414B-B1C1-F789F4F39CDA

P478

Q35061729-3C098C0C-A7C5-4236-B7BD-1291F2C1C418

P50

Q35061729-E7E4DA8F-E62B-4619-8758-3D263CE0FCEB

P577

Q35061729-7608A66A-8664-4F7B-B4E4-C8118CA53FD5

P5875

Q35061729-13B4A0F1-1122-4407-A75B-66E1F2672C47

P698

Q35061729-5DB5E786-320A-4326-BADF-6F05C58E23E5

P921

Q35061729-B4695826-25CF-418F-B350-0C8F2E3AE4E8

P932

Q35061729-2287BB76-82D3-4CB0-BC35-796E14EF3DBE

P356

P1433

Pediatric Blood & Cancer

P1476

A phase II study of Campath-1H ...... ldren's Oncology Group report.

@en

P2093

Anne L Angiolillo

http://www.w3.org/2001/XMLSchema#string

Ashish M Ingle

http://www.w3.org/2001/XMLSchema#string

Gregory Reaman

http://www.w3.org/2001/XMLSchema#string

Peter C Adamson

http://www.w3.org/2001/XMLSchema#string

Rita Secola

http://www.w3.org/2001/XMLSchema#string

P2860

High remission rate in T-cell prolymphocytic leukemia with CAMPATH-1H

Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study.

Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.

The clinical relevance of detection of minimal residual disease in childhood acute lymphoblastic leukaemia

Monoclonal antibodies in the treatment of chronic lymphoid leukemias.

Population pharmacokinetics-pharmacodynamics of alemtuzumab (Campath) in patients with chronic lymphocytic leukaemia and its link to treatment response

Childhood acute lymphoblastic leukaemia and relapse.

The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation.

Epidemiology of hematological malignancies.

The gap between effect of drugs and effectiveness of treatments.

P304

978-983

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/PBC.22209

http://www.w3.org/2001/XMLSchema#string

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

53

http://www.w3.org/2001/XMLSchema#string

P50

P577

2009-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

26700320

http://www.w3.org/2001/XMLSchema#string

P698

19637330

http://www.w3.org/2001/XMLSchema#string

P921

P932

3120889

http://www.w3.org/2001/XMLSchema#string